
Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2025
Description
DelveInsight’s, “Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diffuse Large B-Cell Lymphoma: Overview
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for approximately 25% to 30% of all cases. It typically presents as rapidly enlarging lymph nodes or masses, either nodal or extranodal. DLBCL arises from malignant proliferation of B cells, often originating from germinal center B cells. Genetic mutations, chronic immunodeficiency, and certain infectious agents such as Epstein-Barr virus can contribute to its development. DLBCL is heterogeneous, with various molecular subtypes identified through gene expression profiling. The pathophysiology involves dysregulation of BCL2, BCL6, and MYC genes, among others. Treatment typically involves immunochemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), with the choice of therapy influenced by molecular subtype and clinical staging. Despite its aggressive nature, DLBCL can achieve long-term remission with appropriate treatment, highlighting the importance of early diagnosis and multidisciplinary management. Symptoms of diffuse large B cell lymphoma (DLBCL) can vary but commonly include rapidly enlarging lymph nodes or masses, often presenting as nodal or extranodal involvement. Patients may experience B symptoms such as fever, night sweats, and weight loss, occurring in approximately 30% of cases. Bone marrow involvement is common, seen in up to 50% of patients, while extranodal involvement occurs in about 50% of cases. DLBCL can manifest with symptoms related to compression of adjacent structures, such as superior vena cava syndrome or airway obstruction, particularly in cases of extranodal disease infiltration. Additionally, systemic symptoms (B-symptoms) may result from increased cytokine production. The presentation varies depending on whether the subtype is aggressive or indolent, with aggressive variants typically presenting as rapidly growing masses, while indolent lymphomas may develop more slowly with intermittent or progressive lymphadenopathy.
The diagnosis of diffuse large B cell lymphoma (DLBCL) involves a comprehensive approach including clinical evaluation, laboratory tests, imaging studies, and tissue biopsy. A thorough history and physical examination are essential, focusing on symptoms such as rapidly enlarging lymph nodes, B symptoms (fever, night sweats, weight loss), and signs of extranodal involvement. Laboratory tests typically include a complete blood count with differential, comprehensive metabolic panel, lactate dehydrogenase (LDH) levels, and HIV and hepatitis serologies. Imaging studies, such as positron emission tomography (PET) and computed tomography (CT), are crucial for staging the disease and identifying the extent of involvement. However, the definitive diagnosis of DLBCL relies on tissue biopsy, preferably through an excisional lymph node biopsy rather than fine-needle aspiration, to allow for histologic and immunophenotypic analysis. Immunohistochemistry staining for B cell markers, along with flow cytometry and genetic studies, help confirm the diagnosis and characterize the molecular subtype of DLBCL.
Standard treatment for DLBCL is R-CHOP regimen, comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. High-risk features may necessitate alternative or intensified regimens like R-CHOP combined with lenalidomide or bortezomib. Indolent lymphomas may undergo watchful waiting, radiotherapy, or chemotherapy, while high-grade lymphomas require aggressive chemotherapy with CNS prophylaxis. Supportive care is crucial to manage treatment-related complications, and decisions should involve a multidisciplinary team for optimal outcomes.
""Diffuse Large B-Cell Lymphoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diffuse Large B-Cell Lymphoma pipeline landscape is provided which includes the disease overview and Diffuse Large B-Cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Diffuse Large B-Cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse Large B-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diffuse Large B-Cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diffuse Large B-Cell Lymphoma Emerging Drugs
Further product details are provided in the report……..
Diffuse Large B-Cell Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Diffuse Large B-Cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Diffuse Large B-Cell Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse Large B-Cell Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse Large B-Cell Lymphoma drugs.
Diffuse Large B-Cell Lymphoma Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 7-8 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Diffuse Large B-Cell Lymphoma: Overview
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for approximately 25% to 30% of all cases. It typically presents as rapidly enlarging lymph nodes or masses, either nodal or extranodal. DLBCL arises from malignant proliferation of B cells, often originating from germinal center B cells. Genetic mutations, chronic immunodeficiency, and certain infectious agents such as Epstein-Barr virus can contribute to its development. DLBCL is heterogeneous, with various molecular subtypes identified through gene expression profiling. The pathophysiology involves dysregulation of BCL2, BCL6, and MYC genes, among others. Treatment typically involves immunochemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), with the choice of therapy influenced by molecular subtype and clinical staging. Despite its aggressive nature, DLBCL can achieve long-term remission with appropriate treatment, highlighting the importance of early diagnosis and multidisciplinary management. Symptoms of diffuse large B cell lymphoma (DLBCL) can vary but commonly include rapidly enlarging lymph nodes or masses, often presenting as nodal or extranodal involvement. Patients may experience B symptoms such as fever, night sweats, and weight loss, occurring in approximately 30% of cases. Bone marrow involvement is common, seen in up to 50% of patients, while extranodal involvement occurs in about 50% of cases. DLBCL can manifest with symptoms related to compression of adjacent structures, such as superior vena cava syndrome or airway obstruction, particularly in cases of extranodal disease infiltration. Additionally, systemic symptoms (B-symptoms) may result from increased cytokine production. The presentation varies depending on whether the subtype is aggressive or indolent, with aggressive variants typically presenting as rapidly growing masses, while indolent lymphomas may develop more slowly with intermittent or progressive lymphadenopathy.
The diagnosis of diffuse large B cell lymphoma (DLBCL) involves a comprehensive approach including clinical evaluation, laboratory tests, imaging studies, and tissue biopsy. A thorough history and physical examination are essential, focusing on symptoms such as rapidly enlarging lymph nodes, B symptoms (fever, night sweats, weight loss), and signs of extranodal involvement. Laboratory tests typically include a complete blood count with differential, comprehensive metabolic panel, lactate dehydrogenase (LDH) levels, and HIV and hepatitis serologies. Imaging studies, such as positron emission tomography (PET) and computed tomography (CT), are crucial for staging the disease and identifying the extent of involvement. However, the definitive diagnosis of DLBCL relies on tissue biopsy, preferably through an excisional lymph node biopsy rather than fine-needle aspiration, to allow for histologic and immunophenotypic analysis. Immunohistochemistry staining for B cell markers, along with flow cytometry and genetic studies, help confirm the diagnosis and characterize the molecular subtype of DLBCL.
Standard treatment for DLBCL is R-CHOP regimen, comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. High-risk features may necessitate alternative or intensified regimens like R-CHOP combined with lenalidomide or bortezomib. Indolent lymphomas may undergo watchful waiting, radiotherapy, or chemotherapy, while high-grade lymphomas require aggressive chemotherapy with CNS prophylaxis. Supportive care is crucial to manage treatment-related complications, and decisions should involve a multidisciplinary team for optimal outcomes.
""Diffuse Large B-Cell Lymphoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diffuse Large B-Cell Lymphoma pipeline landscape is provided which includes the disease overview and Diffuse Large B-Cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Diffuse Large B-Cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse Large B-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse Large B-Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.
This segment of the Diffuse Large B-Cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diffuse Large B-Cell Lymphoma Emerging Drugs
- Brentuximab vedotin: Pfizer
- THOR-707: Sanofi
- Abexinostat: Xynomic Pharmaceuticals
- RNK05047: Ranok Therapeutics
- BMF-219: Biomea Fusion
- ADI-001: Adicet Bio
Further product details are provided in the report……..
Diffuse Large B-Cell Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Diffuse Large B-Cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diffuse Large B-Cell Lymphoma
- There are approx. 70+ key companies which are developing the therapies for Diffuse Large B-Cell Lymphoma. The companies which have their Diffuse Large B-Cell Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Diffuse Large B-Cell Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse Large B-Cell Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse Large B-Cell Lymphoma drugs.
Diffuse Large B-Cell Lymphoma Report Insights
- Diffuse Large B-Cell Lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diffuse Large B-Cell Lymphoma drugs?
- How many Diffuse Large B-Cell Lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse Large B-Cell Lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diffuse Large B-Cell Lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diffuse Large B-Cell Lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Miltenyi Biomedicine
- Adicet Bio
- VelosBio
- Novartis Pharmaceuticals
- Sanofi
- Eisai Co
- Schrodinger
- Sana Biotechnology
- Ranok Therapeutics
- Monte Rosa Therapeutic
- Otsuka Pharmaceutical
- OncoNano Medicine
- Regeneron Pharmaceuticals
- Hoffmann-La Roche
- Celgene
- Nurix Therapeutics
- NovalGen
- Nektar Therapeutics
- Genentech
- CSPC ZhongQi Pharmaceutical Technology
- MB-CART2019.1
- ADI-001
- Zilovertamab vedotin
- VAY736
- THOR-707
- Tazemetostat
- SGR-1505
- SC291
- RNK05047
- MRT-2359
- OPB-111077
- ONM-501
- Odronextamab
- Obinutuzumab
- CC-122
- NX-5948
- NVG-111
- NKTR-255
- Mosunetuzumab
- Mitoxantrone Hydrochloride Liposome
Please Note: It will take 7-8 business days to complete the report upon order confirmation.
Table of Contents
240 Pages
- Introduction
- Executive Summary
- Diffuse Large B-Cell Lymphoma: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diffuse Large B-Cell Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Brentuximab vedotin: Pfizer
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- THOR-707: Sanofi
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ADI-001: Adicet Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diffuse Large B-Cell Lymphoma Key Companies
- Diffuse Large B-Cell Lymphoma Key Products
- Diffuse Large B-Cell Lymphoma- Unmet Needs
- Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
- Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
- Diffuse Large B-Cell Lymphoma Analyst Views
- Diffuse Large B-Cell Lymphoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.